Preventing stroke in children with sickle cell anemia in Nigeria
Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria: Community vs Teaching Hospital
This study is trying to set up a program to help prevent strokes in children with sickle cell anemia in Nigeria by training nurses to detect risks and provide treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 217 (estimated) |
| Ages | 2 Years to 16 Years |
| Sex | All |
| Sponsor | Barau Dikko Teaching Hospital Government |
| Locations | 1 site (Kaduna) |
| Trial ID | NCT05434000 on ClinicalTrials.gov |
What this trial studies
This feasibility study aims to establish a stroke prevention program for children with sickle cell anemia in a community hospital in Nigeria. The program involves task-shifting stroke detection and transcranial Doppler ultrasound screening to trained nurses, addressing the high incidence of strokes in this population. By implementing evidence-based practices, including hydroxyurea treatment for those identified at risk, the study seeks to improve access to stroke prevention in resource-constrained settings. The approach includes a needs assessment to identify barriers and building capacity among healthcare providers.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 2-16 years diagnosed with sickle cell anemia who have not experienced a stroke.
Not a fit: Patients who are younger than 2 years, older than 16 years, or have a history of stroke will not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce the incidence of strokes in children with sickle cell anemia in Nigeria.
How similar studies have performed: While similar approaches have been implemented in high-income countries, this specific task-shifting strategy in a low-income setting is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Children with diagnosis of SCA (HbSS or HbSβthal0) 2. 2-16 years receiving care at both YDMH (community hospital) and BDTH (teaching hospital). 3. No previous stroke Exclusion Criteria: 1. Children with SCA younger than 2 years or older than 16 2. Children with stroke 2) Children already on Hydroxyurea
Where this trial is running
Kaduna
- Barau Dikko Teaching Hospital/Kaduna State University — Kaduna, Nigeria (Recruiting)
Study contacts
- Principal investigator: Halima Bello-Manga, MBBS,MPH — Barau Dikko Teaching Hospital/Kaduna State University
- Study coordinator: Halima Bello-Manga, MBBS,MPH
- Email: mamanzara@yahoo.co.uk
- Phone: +2348033470592
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.